Tumour growth delay as a clinical endpoint for the measurement of radiation response.
Tumour growth delay has been investigated as an endpoint of radiation effect in selected patients with superficial metastases measured by calipers and ultrasound. Of 42 patients referred for study with two or more nodules, 17 were suitable for entry into protocols evaluating single or multifraction treatment. The reproducibility of tumour growth delay to the same dose schedule was evaluable in four patients and the sensitivity to 10-20% differences in total dose was evaluable in three patients. No significant size dependency was detected in the response of nodules to radiotherapy and the findings suggest that the growth delay endpoint is sensitive to 20% differences in radiation dose. Evaluable patients with multiple measurable nodules are uncommon but constitute a valuable resource for the testing of biological response modifiers, including radiosensitizers.
D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D002277:Carcinoma / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D002986:Clinical Trials as Topic; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008545:Melanoma / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D009362:Neoplasm Metastasis; D011879:Radiotherapy Dosage; D012878:Skin Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D014463:Ultrasonography